Roche Breast Cancer Pill Cuts Risk of Return by 30% in Study

Roche Holding AG’s experimental pill reduced the risk of an invasive return of a form of breast cancer in a study that underscores the drug’s blockbuster potential.

Patients adding the medicine, giredestrant, to their regimen after surgery were 30% more likely to live without the disease recurring compared with others just taking existing treatments, the Swiss drugmaker said Wednesday. The data stemmed from an intermediate look at a late-stage clinical trial, building on details the company released last month.